Key words: Efficacy, glimepiride, metformin, pioglitazone, safety Introduction Type 2 Diabetes Mellitus (T2DM) is characterized by progressive deterioration in the functions of pancreatic β cells resulting in hyperglycemia, and subsequent complications.In these patients, addition of drugs from other classes is required.
No patient reported poor tolerability as evaluated by patients as well as investigator (table 6).
No hypoglycemic episodes requiring hospitalization were observed during the study period.
The secondary end points included reduction in fasting plasma glucose (FPG), postprandial plasma glucose (PPG) and change in lipid parameters and weight.
Results: At baseline mean age, weight, Hb A1c, body weight, FPG, PPG, C peptide level, LDL-C, triglyceride and HDL-C were similar in three groups.
The mean FPG at baseline in Group A, B and C was 181.76 ± 29.98 mg/dl, 181.24 ± 28.44 mg/dl and 184.92 ± 29.46 mg/dl respectively.
The PPG level in three groups was 278.56 ± 38.86 mg/dl 277.92 ± 28.37 mg/dl and 290.32 ± 36.06 respectively.No hypoglycemic episodes requiring hospitalization were observed in any group. Conclusion: Metformin, glimepiride plus low dose pioglitazone FDC is equally efficacious and well tolerated compared to insulin plus metformin in uncontrolled T2DM.This combination may help in postponing insulin therapy.Position-Shift allows people to shift their public geolocation to protect their privacy and security while on a smart-phone or social network.It enables mobile users to choose who knows where they are and when, giving them full control of their desired privacy.The triple drug combination has been shown to be effective in significantly reducing triglycerides, low-density lipoproteins and total cholesterol in addition to the primary effect of reducing blood sugar.